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Of the three lice (head, body, and pubic louse) that infest humans, the body louse is the species involved in epidemics of louse-
borne typhus, trench fever, and relapsing fever, but all the three cause pediculosis.Their infestations occur today in many countries
despite great efforts tomaintain high standards of public health. In this review, literature searches were performed through PubMed,
Medline, Google Scholar, and EBSCOhost, with key search words of “Pediculus humanus”, “lice infestation”, “pediculosis”, and
“treatment”; and controlled clinical trials were viewed with great interest. Removing lice by hand or with a lice comb, heating
infested clothing, and shaving the scalp were some of the oldest methods of controlling human lice. Despite the introduction of
other resources including cresol, naphthalene, sulfur, mercury, vinegar, petroleum, and insecticides, the numbers of lice infestation
cases and resistance have increased. Todate, viable alternative treatments to replace insecticides have beendeveloped experimentally
in vitro. Today, the development of new treatment strategies such as symbiotic treatment and synergistic treatment (antibiotics +
ivermectin) in vitro has proved effective and is promising. Here, we present an overview on managing and treating human lice and
highlight new strategies to more effectively fight pediculosis and prevent resistance.
1. Lice and Their Public Health Impact
1.1. Overview. Lice have been parasites of humans for thou-
sands of years and differ according to their habitat on the
host [1]. The three sucking lice that infest humans are the
body louse (Pediculus humanus humanus), the head louse
(Pediculus humanus capitis), and the pubic or “crab” louse
(Pthirus pubis) [2]. Body lice and head lice harbor the same
endosymbiotic microorganism that seems to be essential for
the production of nutritional components such as the B
vitamins lacking in host feedings [3, 4]. In 2006, Sasaki-
Fukatsu et al. were the first to describe the phylogenetic
placement of the primary endosymbiont of human body lice;
they identified this endosymbiont as a 𝛾-proteobacterium
and named it Candidatus Riesia pediculicola [5].
Each year, louse infestations still affect hundreds of
millions of people worldwide [6], 6 to 12 million children in
the United States annually [7]. Analysis of data on the global
incidence of pediculosis has shown that this remains a major
health problem in many countries [8].Thus, the head louse is
prevalent in all countries, and outbreaks have been described
at all levels in society [9]. However, children of primary
school age constitute the largest group of people affected [10].
Approximately 6–12 million cases of infestation occur each
year in the United States among children 3–12 years old [11].
Infestation may be increased in school children with more
siblings and of lower socioeconomic group [12]. The pubic
louse is usually a sexually transmitted organism, although
atypical locations such as eyebrows and eyelashes have been
reported [9, 13].The body louse lives in clothes andmultiplies
when cold, promiscuity, lack of hygiene, and war are present.
Its prevalence also reflects the socioeconomic level of society
[14]. During the civil wars in Burundi, Rwanda, and Zaire in
the 1990s, the prevalence of lice infestations reached 90–100%
[15]. The body louse is the species known to be involved in
epidemics of louse-borne infectious diseases [16], but all the
Hindawi Publishing Corporation
BioMed Research International
Volume 2016, Article ID 8962685, 12 pages
http://dx.doi.org/10.1155/2016/8962685
2 BioMed Research International
three cause pediculosis which is highly contagious and easily
transmitted by close body-to-body contact or contact with
infested linen, brushes, or clothes, according to the species of
louse. A louse-infested person can be infested by thousands
of lice, each of which bites on average five times per day for
body lice [17]. In literature, several methods were used to
get rid of lice infestations. Thus, this review summarizes the
management methods and various strategies used in treating
these hematophagous parasites.
1.2. Physiology and Exponential Multiplication of Lice. Hu-
midity is a critical factor for lice; the optimal humidity for
survival is in the range of 70–90% [9]; they cannot survive
when this value falls below 40%. Temperature is also highly
influential on the louse’s physiology. According to Maunder,
laboratory lice prefer a temperature between 29 and 32∘C [9].
At 50∘C, body lice die, and this temperature is critical when
washing clothes, as water and soap alone will not kill lice
[43]. Although eggs can survive at lower temperatures, their
viability is limited to 16 days [43].
A louse typically feeds five times a day and each female
can have several successive partners. At maturity, lice can
mate every day and each female lays 8–10 eggs per day, with a
female able to lay up to 300 eggs during her lifetime. During
the prolonged mating process, both the male and the female
will continue to feed [9]. Eggs are laid in the folds of clothing
for body lice and in the hair for head lice; they are held in place
by an adhesive produced by the mother’s accessory gland
[13]. Hatching occurs 7–10 days after laying. There are three
nymphal stages (L1, L2, and L3), moulted the third, fifth, and
tenth days after hatching andwhich are differentiated by their
size.
1.3. Remarks on the Genetics of the Louse (Body Lice versus
Head Lice) and Its Symbiont. Genetic tools were used to
separate human lice into head lice and body lice. The first
study was based on the 18S rRNA gene [44], and subsequent
studies focused on mitochondrial genes [45–47] and inter-
genic spacers [48, 49]. These studies revealed that there are
three clades of head lice, one of which may also be body
lice (clade A) [46, 47]. Subsequently, a fourth clade including
both head and body lice was detected in Congo [50]. A
transcriptome study of human head and body lice revealed
that there is only one gene present in body lice but not in head
lice. Otherwise, the main differences identified between head
lice and body lice concern gene expression levels [51]. Indeed,
14 putative differentially expressed genes were identified by
comparing head louse and body louse data. However, head
lice and body lice have almost the same genomic content but
are phenotypically different (different ecotypes) as a result of
differential gene expression [52].Thus, a rapidmultiplex real-
time PCR assay was established that differentiates between
head and body lice with 100% specificity and sensitivity [53].
Based on these studies, we can suggest that the clade A head
louse has a deleted genome and originated from the body
louse. The opposite hypothesis was considered evident for
years [9, 45, 54].
The primary endosymbiont of human body lice is a
bacterium belonging to the family Enterobacteriaceae in the
𝛾-Proteobacteria class [5]. Organs called mycetome host the
primary endosymbiont, except during passage to the ovaries
for transovarial transmission [55]. A recent study of the
genome of Candidatus Riesia pediculicola revealed a small
genome, 574 kB, similar to what is found in other insect pri-
mary endosymbionts [56]. The reduction in genome size and
the high AT-bias suggest an ancient association between the
louse and its primary endosymbiont [56]. Thus, Candidatus
Riesia pediculicola is an insect primary endosymbiont (P-
endosymbiont) that has been associatedwith the louse for 13–
25 million years [52].
1.4. Louse-Borne Infectious Diseases. Louse-borne diseases
are associatedwith a high prevalence of body louse infestation
and have recently reemerged in jails and refugee camps in
central and eastern Africa [15], in rural communities in the
Peruvian Andes [57], in rural populations in Russia [58], and
in homeless populations living in poor hygiene conditions in
developed countries [59–63]. Given the phagocytic activity
of their immune system, it is more likely that body lice are
vectors of pathogens than head lice [64]. The physiological
difference between head and body lice is that head lice do
not transmit human diseases, whereas body lice are vectors
of bacterial diseases transmitted to humans, including trench
fever caused byBartonella quintana, relapsing fever caused by
Borrelia recurrentis, and epidemic typhus caused by Rickettsia
prowazekii [1, 57, 65]. Acinetobacter baumannii was found in
21% of the 622 body lice collected worldwide [66], but the
transmission of the infection A. baumannii by body louse
has not yet been demonstrated. In Morocco in the 1940s, the
causative agent of plague,Yersinia pestis, was recovered froma
body louse collected from a septicemic patient [67, 68]. In the
Democratic Republic of the Congo, DNA from Yersinia pestis
was observed in one head louse and two body lice [50, 69].
In addition, the experimental model to evaluate the human
body louse as a vector of plague has been demonstrated in
our laboratory [70].
Head lice can carry pathogens although their role as a
vector has not yet been clarified. DNA from B. quintana was
found in head lice from Nepalese children in 2006 [71], from
homeless individuals in the USA in 2009 [65], and from the
local population in Congo, Madagascar, and Senegal [72]. It
was also found in head louse nits from a homeless person
in Marseille, France [73], and in head lice from Ethiopian
[74] and Senegalese [75] patients. DNA from A. baumannii
was detected in 33% and 3% of the head lice collected from
schoolchildren in Paris, France [76], and Diankabou, Mali,
respectively [77].
2. Diagnosis of Lice Infestations
Lice infestation is a common problem and diagnosis is gen-
erally based on the presence of nits or lice. The characteristic
itching or pruritus that accompanies infestation may in some
cases be complicated by bacterial infections (Figures 1(a) and
1(b)) that occur when the skin becomes excoriated [78, 79].
Lice may be seen on the scalp, in the hair, or on clothing
of the infected person. However, the techniques used for
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Figure 1: Nuisance related to lice: (a) scalp infection caused by head lice; (b) scraping lesions related to body lice infestation.
diagnosing a louse infestation (Pediculus humanus) are a
source of controversy. Most epidemiological studies have
used direct visual examination (visual inspection). Direct
visual examination (Figure 2(a)) with a magnifying glass and
combing with louse comb (Figures 2(b) and 2(c)) are two
frequently usedmethods; but the first is not a reliable method
for diagnosing living lice onhair [80]. It underestimates active
infestation and is only useful with heavily infested patients.
Elsewhere, Balcioglu et al. have demonstrated in their study
that plastic detection comb is better than visual screening for
diagnosis of head louse infestation [81].
3. Treatment Strategies
The fight against pediculosis is certainly a very ancient
concern and various methods have been used to get rid of
it.
3.1. Historical Methods. Removing lice by hand (Figure 2(a))
or with a lice comb (Figures 2(b) and 2(c)) and shaving the
scalp were some of the oldest methods of controlling human
lice [82, 83].
3.1.1. Using Hands. This was the first means used before the
comb was invented. Crushing lice with your fingers should
be strongly discouraged because it can lead to bacterial
penetration through the cutaneous route. Manual removal
of nits (especially the ones within 1 cm of the scalp) can
only be recommended after treatment with a product [84].
One study showed that manual removal is less effective than
pediculicides and does not improve results even when used
in addition to a pediculicide treatment [35].
3.1.2. Using Combs. Combs for the removal of adult lice and
nits have been used since ancient times [82]. Today, many
different types of combs are sold to control lice. Combing can
be undertaken every 1–3 days. This method not only is for
treatment but can be for prevention, to remove mature lice
which might otherwise lay eggs and perpetuate the life cycle.
However, it was also demonstrated that the diagnosis of louse
infestation using a louse comb is four times more effective
(25% versus 6%) than direct visual examination and twice
(57 seconds versus 116 seconds) as fast [80]. This study was
proven by Balcioglu and colleagues in 2008 [81]. Compared
to phenothrin in clinical trials, the bug busting method is
effective for managing head lice infestation [41].Thus, we can
conclude that using a louse comb to screen patients for lice
infestation and treating with a pediculicide are effective.
3.1.3. Shaving. Head shaving can be a simple method to
remove the lice and eggs. It was noted that short hair
does not prevent head lice infestations [78]. However, head
shaving should be avoided whenever possible because it is
humiliating, especially for girls. Complete shaving of the
head generally does eliminate lice and prevents reinfestation
but is rarely an appropriate measure to take in response to
infestation [85].
3.1.4. Using Heat. A further step is heating infested clothing
and bedding with hot water to destroy all stages of lice.
The heat necessary for the destruction of both lice and nits
is 52∘C for 30 minutes [86]. This method can be easily
applied to infested clothes using hot water but cannot be used
on infested hair. Lice may, however, make themselves heat
resistant by a hormonal process. Heat resistance is achieved
by lice excreting heat resistant, protective secretion through
their outer skeleton. This is part of the natural defense
mechanism of lice. When the lice have become heat resistant,
they can tolerate very high temperatures (above 100∘C) [87].
3.1.5. Chemical Products. Cresol, naphthalene, sulfur, mer-
cury, petroleum, naphthalene, and petrolatum were
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Figure 2: A few historical methods to get rid of lice. (a) Detecting lice or nits by direct visual examination; (b) wooden comb found at Ein
Rachel (Negev Desert) (100 BC–200AD) containing 10 head lice and 5 nits; (c) modern plastic comb.
employed alone or, for some of these products, in combina-
tion with oil or vinegar [83, 88]. Due to major adverse
effects and/or resistance, all of these methods have now been
discontinued.
3.2. Local Products
3.2.1. Study Methods: Sensitivity and Resistance. Measure-
ment of the susceptibility or resistance per se may be
performed only by using doses of insecticide applied via an
inert carrier, and this is the basis of the WHO tests and their
variants [89–93]. The majority of studies have used WHO-
recommended protocols [94] or modified versions of those
techniques. Studies have sought to measure the effective-
ness of pediculicides in controlled laboratory test systems.
Measurement of sensitivity to insecticide in formulations
cannot be generic and must be measured either in vivo by
means of a clinical trial or in vitro/ex vivo by using the
whole formulation [95]. The methodology of ex vivo tests
conducted by Meinking and colleagues [96, 97], in which the
lice were allowed to continuously bubble on wet sponge with
pediculicidal and without subsequent washing, may have
given unrepresentative results in some cases. Two studies
evaluated resistance to permethrin using techniques on the
basis of a WHO method employing single concentration
applications of insecticide to filter papers andmeasuring time
to death of the test insects, in order to record LT50 and LT95
[94]. However, in one of these studies the levels of insecticide
used to measure the lethal dose were considerably lower than
those recommended by WHO [98], so in some cases the
measure may have been more of vigor tolerance (reduced
sensitivity of an insect population due to elimination of
the least robust insects by weak selection) than resistance
[99]. Tests using laboratory-reared body lice may be less
discriminatory than tests employing wild-caught head lice,
and they do not identify variations of effectiveness likely to
arise as a result of selection pressure [96]. Observations of
lice that survived adequate clinical applications of insecticide
products containingmore than 13% of monoterpenes suggest
they have already become resistant to these chemicals [95].
3.2.2. Pediculicides. Since World War II, many insecti-
cides have been used against lice. Among those for treat-
ment of head and body lice were organochlorines (DDT,
lindane), organophosphates (malathion), carbamates (car-
baryl), pyrethrins (pyrethrum), andpyrethroids (permethrin,
BioMed Research International 5
Table 1: Main products used in clinical trials in humans: efficacy and safety.
Comparison of treatments Efficacy Safety References
1,2-Octanediol versusmalathion More effective Adverse effects reported [18]
1,2-Octanediol versus placebo Effective No serious adverse events [19]
Cocamide DEA versus permethrin May be as effective Adverse effects reported [20]
Phenothrin versus wet-combing May be as effective No evidence of harms from combing [21]
Tocopheryl acetate versus
permethrin More effective No adverse effects reported [22]
Dimeticone versus permethrin More effective No serious adverse events [23, 24]
Dimeticone versusmalathion More effective No adverse effects reported [25]
Dimeticone versus dimeticone plus
nerolidol As effective No adverse effects reported [26]
Dimeticone 4% lotion versus
phenothrin Equally effective Few adverse effects reported [27]
Ivermectin versusmalathion As effective No major adverse effects observed [28, 29]
Ivermectin versus placebo (vehicle) More effective No adverse effects reported [30]
Malathion lotion versus phenothrin More effective No adverse effects reported [31]
Malathion versus permethrin More effective No adverse effects reported [32]
Lindane versus permethrin As effective Adverse effects reported [33]
Permethrin versus lindane More effective No adverse effects reported [34]
Permethrin versus combing More effective No adverse effects reported [35]
Permethrin versus placebo More effective No adverse effects reported [36]
TMP-SMX plus permethrin versus
permethrin alone More effective No major adverse effects reported [37]
Combined insecticides versus
herbal oils As effective No clinically detectable adverse effects [38]
Soya oil-based shampoo versus
permethrin More effective No serious adverse events [39]
Coconut and anise in spray versus
permethrin More effective Adverse effects reported [40]
Combing versus phenothrin More effective No evidence of harms from combing [41]
Bug Buster kit versusmalathion or
permethrin More effective No information on adverse effects [42]
phenothrin, and bioallethrin) [82]. Most of these pediculi-
cides were tested in clinical trials to assess their effectiveness
and safety (Table 1). However, their pediculicidal and ovicidal
efficacy may vary by product components (Table 2).
(1) Dichlorodiphenyltrichloroethane (DDT) and Lindane. Or-
ganochlorines (DDT and lindane) were the first of the
synthetic organic insecticides used.The development of DDT
during the 1940s had enormous impact. It was immediately
used to dust prisoners of war to control body lice and
won wide acceptance, not only for use on humans but
also for animals [100]. Lindane has been available since
1951. However, its effectiveness has been compared to other
products [33, 34]. Physiological resistance among both head
and body louse populations to lindane is widespread [101].
These two organochlorides are neurotoxic for parasites. Due
to developed resistance [91] and safety concerns, the use of
these products should be discussed [6].
(2) Malathion. An organophosphorous insecticide formu-
lated in concentrations of 1.0% and 0.5%, malathion, has
been widely used in the USA and Europe. It worked rapidly
against adult lice and was usually effective ovicide [102]. Its
effectiveness has been tested in clinical trials [31, 32, 42].
However, resistance of body lice to malathion has been
reported in Burundi [103] and Ethiopia [104]. In France, head
lice resistance tomalathion is reported to be based on clinical
failure to control infestations [105]. In addition, a randomized
study in 22 volunteers found no evidence that malathion was
dangerous in the treatment of head lice when the products
were applied in accordance with the instructions for use
[106]. However, its use in children under 6 months should be
avoided [6].
(3) Carbaryl. Used since 1976, more recent reviews have
reported carbaryl to be less effective than previously thought
[107]. Potentially carcinogenic in rodents, its prescriptionwas
restricted in UK [6].
(4) Natural Pyrethrins or Synthetic Pyrethroids (Phenothrin).
These pyrethroids are closely related to permethrin and
are combined with a synergist (piperonyl butoxide) or
6 BioMed Research International
Table 2: Main formulations of physical acting and insecticide-based products available in France.
Physical acting products Principal component(s) Insecticide-basedproducts
Principal
component(s) Activity
Pouxit XF Extra Fort
Dimeticone-1.6, dodecatrien-3-ol
3,7,11-trimetyl PEG/PPG dimeticone
co-polymersilica silylate
Prioderm Malathion 100% pediculicidal
and ovicidal
activity
Duo LP Pro Triglycerides, lipid esters(Oxyphthirine)
Itax Oily silicone based complex
100% pediculicidal
activity and
insufficient
ovicidal activity
Altopou Cyclomethicone 5, dimeticone Marie-Rose Pyrethrin
Pouxit Cyclomethicone 5, dimeticone Para Special Poux Alethrin(prallethrin)
Paranixmousse Dimeticone, paraffin oil Para Plus Malathion,permethrin
Paranix new formule
action double Dimeticone, mineral oil
Marie-Rose une seule
application
Cocamidopropyl betaine cocamide
DEA
Parasidose lotion
traitante
Ricinus, paraffin, cocamide DEA,
cocos Pyreflor lotion Permethrin 25/75 Insufficient
pediculicidal
activity and
insufficient
ovicidal activity
Parasidose nouvelle
formule Biococidine Biococidine Sklice lotion Ivermectin
Yapapou Cocos nucifera, cocamide DEA,citric acid, cocamidopropyl
Poux Apaisyl Coconut oil derivatives
nonsynergist insecticide (permethrin) [6]. Like malathion,
these products can be a fire danger, and burns have been
reported [108]. As with permethrin, resistance to this com-
pound has already appeared in France [109], UK [110],
and the Czech Republic [111]. In clinical trials, phenothrin
has been demonstrated to also be more effective than wet-
combing [21]. It seems likely that resistance to pyrethroids
will develop much more rapidly than was the case with older
compounds [112]. However, many studies worldwide have
already described resistance to pyrethrins and pyrethroids
[91, 99, 113].
(5) Permethrin. Synthetic pyrethroid, introduced for the first
time in the 1986s, 1% permethrin, was approved and was
available over the counter for use in 1990 [114]. It is one of the
most frequently used treatments against human ectoparasites
(head lice and scabies) among lindane, malathion, and
carbaryl [34, 115]. However, resistance to permethrin has
been reported in many studies throughout the world [116–
120]. In clinical trial, permethrin compared to soya oil-based
shampoo, coconut, and anise in spray has been less effective
[39, 40].
(6) Dimethicone. Some studies found dimethicone to be a
safe product and more effective than permethrin [121]. In
their randomized controlled trial, Burgess et al. confirm
efficacy of a single application of 4% dimeticone liquid gel
in comparison with two applications of 1% permethrin [23].
Used in many clinical trials, its effectiveness may depend on
product [24–27, 122]. However, resistance to dimethicone is
unlikely due to its physical mode of action [114].
(7) Oxyphthirine. The Oxyphthirine lotion in a single appli-
cation in treatment of human lice infestations was revealed
to be the safest as it was shown to be nonflammable. The
product showed a high efficiency (100%) and certain ability
to remove attached nits [123]. The lotion, a patented meta-
emulsion suitable for treatment of humanhead lice (Pediculus
capitis), has a mechanical action that asphyxiates lice and nits
[123].
(8) Benzyl Benzoate/Benzyl Alcohol. In concentrations of 10%
to 30%, this substance has been widely used for treatment
of pediculosis and scabies, although it is not always effective
ovicide. This product may cause allergic reactions and skin
irritations. It is no longer registered for lice control in the
USA, and in Canada it is only available on prescription
[112]. Benzyl alcohol 5% is nonneurotoxic and kills head
lice by asphyxiation. Its side effects are pruritus, erythema,
pyoderma, and ocular irritation [114].
(9) Spinosad. Spinosad 0.9% topical suspension is a new ovi-
cidal and pediculicidal treatment against head lice created by
fermenting Saccharopolyspora spinosa, a bacterium found in
the soil [124]. However, the most common adverse reactions
observed include erythema, ocular irritation, and irritation at
the application site [125].
(10) Other Products. 1,2-Octanediol, cocamide diethanol-
amine lotion (cocamide DEA), and tocopheryl acetate 20%
were tested in clinical trials against head lice to assess
their efficiency and safety (Table 1) [18–20, 22]. However,
the adverse effects were reported with 1,2-octanediol and
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cocamide diethanolamine except tocopheryl acetate. Thus,
continued study is recommended to establish long-term
safety of new and alternative agents [126].
3.3. Per Os Treatment. As all other external treatments, per
os treatment may have more secondary effects.
3.3.1. Ivermectin. Macrocyclic lactone, ivermectin, is widely
used throughout central and western Africa as a microfi-
laricide to control the transmission of human onchocerci-
asis and Bancroft filariasis and has been effective against
ectoparasites and nematodes in veterinary medicine. It is
similar to macrolide antibiotic agents but without antibac-
terial activity. Clinicians have explored using ivermectin for
human ectoparasitics, specifically for head lice (and scabies).
In clinical trials, its effectiveness has been compared to other
products [29, 30]. Ivermectin appears to provide encouraging
results in the treatment of head lice [127] with a need for
further doses [128], despite a potential resistance to this
molecule being demonstrated in laboratory conditions [129].
However, in a cohort of homeless subjects in Marseilles,
France, a prevalence of 85% for body lice was observed
[130]. This infestation was reduced temporarily to 19% with
three doses of oral ivermectin administered at seven-day
intervals [130]. Currently, resistance to ivermectin has been
widely demonstrated in many arthropods [131, 132] and is an
increasing problem for ectoparasite and nematode control. In
clinical trials, oral ivermectin, given twice at a 7-day interval,
may be more effective [28] or as efficacious [29] as topical
0.5% malathion lotion.
3.3.2. Cotrimoxazole. Although this product (trimetho-
prim/sulfamethoxazole, TMP/SMX) has also been reported
as a treatment in head lice [133], these compounds are not
currently recommended for controlling body lice. Moreover,
using this molecule as a pediculicide was stopped due to
themultiple adverse effects (nausea, vomiting, rash, transient
pruritus, and allergic-type reactions) recorded in participants
in clinical trials [37].
4. New Approaches
The posttreatment reemergence of lice is common and still
remains a real challenge. Treatment success depends on
improving our knowledge of the fundamental biology and
physiology of the louse.
It is important to notice that per os treatment may have
more secondary effects as all other oral medicines than
external products.
4.1. Symbiotic Treatment. Only a few P-endosymbionts have
been described among 14,000 species of hematophagous
insects [134, 135]. The endosymbiont Candidatus Riesia
pediculicola (Figure 3(a)) is a microorganism hosted by
body (Pediculus humanus corporis) and head lice (Pediculus
humanus capitis) that appears to be essential for the pro-
duction of nutritional components such as the B vitamins
lacking in host feeding [3, 4]. In our laboratory, we developed
an experimental in vitro feeding model using an artificial
membrane to demonstrate that doxycycline (an antibiotic
belonging to the family of tetracyclines) given at different
doses (10, 20, and 50 𝜇g/mL) daily for up to 10 days affects
the endosymbiont of lice (Figure 3(b)) and also decreases
egg production [136]. It was demonstrated that the symbiont
Candidatus Riesia pediculicola is a possible target for the
development of louse-control strategies [56], because loss of
these bacteria would mean the death of their hosts. However,
symbiotic treatment remains promising and it would be
interesting to evaluate the effectiveness of other drugs alone
or in combination on lice by targeting their endosymbiont
bacterium.
4.2. Synergistic Treatment (Antibiotics + Ivermectin): Figures
3(c) and 3(d). Several compounds, including antibiotics,
have been shown to increase intracellular concentrations
of macrocyclic lactones [137]. Indeed, antibiotics such as
doxycycline, erythromycin, or azithromycin were recom-
mended to treat some infections linked to lice [138]. In
addition, it was shown that drug combinations including
ivermectin provide antifilarial activity with ancillary benefits
on intestinal helminths and ectoparasites, such as chiggers
and lice [139]. However, in experiments with adult worms,
when doxycycline was combined with macrocyclic lactones
in ivermectin the effectiveness was approximately 80% versus
9% for treatment with doxycycline alone [140, 141].The effec-
tiveness of this combination has also been confirmed in nat-
urally infected dogs with Dirofilaria immitis [142]. Recently,
in our laboratory we have demonstrated the effectiveness
of drug combinations (especially doxycycline + ivermectin,
erythromycin + ivermectin, rifampicin + ivermectin, and
azithromycin + ivermectin) on body lice reared on rabbits in
our laboratory [143]. Thus, we conclude that the synergistic
effect is one of the most effective means of lice treatment and
also prevents reemergence and resistance.
5. Future Efforts
Lice have been intimately associated with humans for cen-
turies. Infestations are increasing worldwide due to insec-
ticide resistance. To date, viable alternative treatments to
replace insecticides have been developed experimentally in
vitro. However, it will be interesting to develop thesemethods
in vivo in other studies in order to achieve the complete
eradication of lice and avoid the selection of a resistant
population of lice. Thus, future efforts should be directed
toward the development of pediculicides based on new
chemicals such as avermectins and antibiotics.
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